Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Neuropeptides and their receptors: innovative science providing novel therapeutic targets Brain SD; Cox HMBr J Pharmacol 2006[Jan]; 147 Suppl 1 (Suppl 1): S202-11This review examines our current understanding of the roles of some of the best known neuropeptides that have played major roles in our combined research programmes. Evidence obtained from over 75 years of research shows involvement of these transmitters in a wide range of organs relevant to cardiovascular, respiratory, cutaneous, neuronal and intestinal systems. There is an increasing understanding of the mechanisms involved in the release of the peptides (substance P and calcitonin gene-related peptide (CGRP)) from sensory nerves or, neuropeptide Y (NPY) from sympathetic, parasympathetic and nonadrenergic, noncholinergic (NANC) neurons. Responses in target tissues result from interactions of the neuropeptides, or related forms, with specific G-protein coupled receptors (GPCRs or 7 transmembrane-spanning, 7TM proteins) that belong to either rhodopsin-like, class 1 (neurokinin (NK) and NPY Y receptors) or secretin-like, class 2 GPCRs (CGRP receptors). The majority of receptors activated by our chosen neuropeptides are now cloned, with knowledge of preferred agonists and selective antagonists for many receptor subtypes within these families. The study of neuropeptides in animal models has additionally revealed physiological and pathophysiological roles that in turn have led to the ongoing development of new drugs, through utilization predominantly of antagonist activities.|Animals[MESH]|Anti-Anxiety Agents/pharmacology[MESH]|Anti-Obesity Agents/pharmacology[MESH]|Calcitonin Gene-Related Peptide/physiology[MESH]|Humans[MESH]|Neuropeptide Y/physiology[MESH]|Neuropeptides/*physiology[MESH]|Peptide YY/physiology[MESH]|Receptors, G-Protein-Coupled/agonists/antagonists & inhibitors/*physiology[MESH]|Receptors, Neuropeptide/agonists/antagonists & inhibitors/physiology[MESH]|Sensory Receptor Cells/metabolism[MESH]|Substance P/physiology[MESH]|Vasodilator Agents/pharmacology[MESH] |
